PEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP


Denise Rokitka, MD, MPH



- Describe incidence of childhood cancer and survival rates and causes of early mortality.
- Understand the late effects of cancer treatment and the variables involved.
- Understand the benefits of screening and early detection as a means of prevention of late complications of cancer therapy.

Childhood Cancer Incidence


Childhood Cancer Incidence Over Time (per 100,000)




Source: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER 9 area. Age 0-19.

Survival Rates

5-Year Survival Rate, Age 0-19






Mortality Data

<u>J Clin Oncol.</u> 2009 May 10;27(14):2328-38. doi: 10.1200/JCO.2008.21.1425. Epub 2009 Mar 30.

Causes of death



Int J Cancer. 2016 Jul 15;139(2):322-33. doi: 10.1002/ijc.30080. Epub 2016 Mar 30

About Survivors

- Survivors do not have complete knowledge of their diagnosis and treatment.
 - Approximately 30% of survivors can not accurately report their diagnosis.
 - Approximately 10% of patients do not recall receiving chemotherapy.
 - Only 30-50% recall receiving anthracyclines.
 - Approx. 30% are unaware of their risk for late effects.
 - Approximately 10% of patients do not recall receiving radiotherapy.

Late Effects

- Adverse long term health related outcomes that are dependent upon the therapeutic regimen a patient received as part of cancer therapy.
- Adverse events can occur months or years after cancer treatment.

Late Effects

Causes

- Location and extent of primary disease
- Type and dose of cancer therapy
- Genetic predisposition
- Host factors
 - Gender
 - Health habits
 - Age at time of treatment
 - Era of treatment

Late Effects- Genetics


Gene	Primary malignancy(s)	SMN type(s)		
RB1 ^{43,44}	Retinoblastoma (RB)	Soft tissues sarcomas, osteosarcoma, melanoma, CNS malignancies		
BRCA1/245	Primary Breast	Contralateral breast cancer, GI malignancies, ovarian tumors		
NF1 46,47	Optic pathway gliomas	Malignant peripheral nerve-sheath tumors, gliomas, t-AML		
TP5348,49	Li-Fraumeni Syndrome: tumors of the breast, CNS, adrenocortical carcinomas, soft tissues sarcomas, leukemias (rare)			
MLH1 ⁴⁵ , MSH2, MSH6	Hereditary Nonpolyposis Colorectal Cancer Syndrome (HNPCC or Lynch Syndrome): colon cancer, female reproductive cancers, other Gl cancers			
VHL ^{47,50}	Von-Hippel Landau Syndrome: hemangioblastoma, renal cell carcinoma, pheochromocytoma			
DICER1 ^{51,52}	DICER1 Syndrome: pleuropulmonary blastoma, cystic nephroma, ovarian tumors, soft tissue sarcomas			

Choi, D. K., Helenowski, I. and Hijiya, N. (2014), Secondary malignancies in pediatric cancer survivors: Perspectives and review of the literature. Int. J. Cancer, 135: 1764–1773. doi:10.1002/ijc.28991


Late Effects


- 24 yo survivor has the same cumulative incidence of a grade 3-5 health condition as a 50 sibling.
- By age 50, 23% of survivors had 2 or more severe, disabling, lifethreatening, or fatal health condition compared with only 4.3% of sibs.
- 25% of 'healthy' survivors had a new grade 3-5 health condition within 10 years.

<u>J Clin Oncol.</u> 2014 Apr 20;32(12):1218-27. doi: 10.1200/JCO.2013.51.1055. Epub 2014 Mar 17.



Late Effects





Any Cancer Experience-Psychosocial Issues

- Increased risk for smoking, drinking, and other risky behaviors
- Increased risk for not completing school
- Poor body image and self-esteem
- Social Withdrawal
- Increased risk of mental health disorders
 - Depression and anxiety
 - Post-traumatic stress
 - Chronic Fatigue

Any Cancer Experience-Psychosocial Issues

- Risk Factors
 - Female gender
 - Adolescents and Young Adults
 - Prior Trauma
 - Previous mental health history
 - Poor support system
 - Family History of Mental Health disorders
 - CNS cancer or Bone Marrow Transplantation
 - Low Socioeconomic status

Chemotherapy

- Anthracyclines- Doxorubicin, Daunorubicin
- Epipodophyllotoxins- Etoposide
- Alkylating agents- Cytoxan
- Radiation- Cranial or Craniospinal
- Bone Marrow Transplant


Chemotherapy

Anthracyclines

Dilated cardiomyopathy and arrhythmias

- Doxorubicin
- Daunorubicin
- Idarubicin
- Mitoxantrone

Cardiac Toxicity




RECOMMENDED FREQUENCY OF ECHOCARDIOGRAM (or comparable cardiac imaging)						
Age at Treatment*	Radiation with Potential Impact to the Heart ^s	Anthracycline Dose [†]	Recommended Frequency			
	Yes	Any	Every year	8		
<1 year old	No	< 200 mg/m ²	Every 2 years	incidence		
		≥ 200 mg/m ²	Every year	ide		
1-4 years old	Yes	Any	Every year			
	No	<100 mg/m ²	Every 5 years	umulative		
		≥100 to <300 mg/m ²	Every 2 years	ula		
		≥300 mg/m ²	Every year	E.		
≥5 years old	Yes	<300 mg/m ²	Every 2 years			
		≥300 mg/m ²	Every year			
	No	<200 mg/m ²	Every 5 years			
		≥200 to <300 mg/m ²	Every 2 years			
		≥300 mg/m ²	Every year	(%)		
Any age with decrease in serial function Every year						
Any age with decrease in serial function Every year *Age at time of first cardiotoxic therapy (anthracycline or radiation [see Section 81], whichever was given first) *See Section 81 *See Section 81 *Based on doxorubicin isotoxic equivalent dose [see conversion factors on previous page, "Info Link (Dose Conversion)"] *Based on doxorubicin isotoxic equivalent dose [see conversion factors on previous page, "Info Link (Dose Conversion)"]						
				tive		


http://www.survivorshipguidelines.org/pdf/LTFUGuidelines_40.pdf


https://doi.org/10.1136/bmj.b4606 (Published 09 December 2009)

Cardiac Toxicity




Myocardial infarction





Time since diagnosis (years)



Time since diagnosis (years)

Cumulative incidence (%)

Chemotherapy

- Secondary Malignancies
 - Epipodophyllotoxins- Etoposide
 - Anthracyclines
 - Alkylating agents
 - Nitrogen Mustard
 - Cytoxan
 - Stem Cell Transplant
 - Radiation

Second Malignant Neoplasms

Primary Diagnosis	Ν	Breast	Thyroid Cancer	CNS Tumors	Sarcoma	Bone	Leukemia	Melanoma	Lymphoma	GI Carcinomas	NMSC
HL	247	94	36	7	19	6	14	11	14	14	163
Leukemia	152	16	23	45	4	4	9	11	10	2	138
Soft tissue sarcoma	80	10	7	3	18	12	3	6	2	2	23
Bone cancer	74	21	9	3	5	9	6	5	1	7	20
CNS tumor	68	3	12	18	6	5	3	4	4	2	40
NHL	43	6	7	4	2	5	2	2	4	2	27
Neuroblastoma	33	2	8	1	4	0	4	0	1	0	6
Wilms tumor	33	5	2	0	7	5	2	3	0	4	13
Total	1,160	157	104	81	65	46	43	42	36	33	430

Chemotherapy

- Infertility or Premature Ovarian Failure
 - Nitrogen Mustard
 - Dacarbazine
 - Procarbazine
 - Cytoxan
- Avascular Necrosis/ Osteopenia/ Osteoporosis-Steroids
- Pulmonary Fibrosis- Bleomycin

Radiation

Cranial


- Growth hormone deficiency
- Metabolic Syndrome
- Endocrine Dysfunction
- Hearing loss
- Visual disturbance / Cataracts
- Dental caries
- Neurocognitive Deficits
 - Executive Functioning, Learning issues
- Secondary Malignancies
 - Thyroid dysfunction
 - Breast Cancer
 - Thyroid Cancer

Radiation

Liver/Spleen dysfunction

Premature births/ Low Birth weight/ Small for gestational age

Radiation-Abdominal Tumors




Am J Obstet Gynecol 2002;187:1070-1080

Skin Cancer

- Non-melanoma skin cancer is the most frequently diagnosed secondary malignant neoplasm.
 - Locations include head and neck (43%), back (24%), chest (22%), abdomen and pelvis (5%), extremity (3%) and unknown (4%).
 - Ninety percent of non-melanoma skin cancers occur in prior areas of radiation.

Brain Tumor- Stroke Risk





- Abdominal Tumors
 - Bowel obstruction
 - Chronic abdominal pain
 - Poor GI motility
- Musculoskeletal problems
 - Leg length discrepancies
 - Pain
 - Disability from limb sparing surgery

Pregnancy Outcomes- Offspring


	Offspring of Survivors (N = 2198)	Offspring of Siblings (N = 4544)
Chromosomal Syndrome	0.2% (4)	0.1% (6)
Single Gene Disorder	0.6% (14)	0.2% (10)
Major Congenital Malformation	2.7% (59)	2.8% (127)

Am J Hum Genet 1998;62:45-52

Prevention

- Health maintenance age appropriate monitoring, age appropriate general health screening including cancer screening, eye exams, dental exams
- Exposure related screening cardiac, second malignant neoplasms, pulmonary disease, neuropsychological screening, psychosocial screening
- Patient education risk reduction (alcohol, tobacco, exercise, sun exposure), anticipatory guidance (e.g. fertility and pregnancy)

https://childrensoncologygroup.org/index.php/survivorship guidelines



The Good News!!!

